Abstract: Compounds having the following structure: wherein Y= wherein: [R2bR2a] represents a reaction product between R2b and R2a of Formulas (2) and (1), respectively, R3 functions as a cell penetration moiety, and R1 functions as a binding moiety to bind to the payload (P) to form a conjugate with P, wherein R1, R3, A, D, L1, L2, L3, L4, L5, L6, L7, r, m, s, n, p, and q are as defined in further detail elsewhere in this disclosure. Also described herein are methods of producing compounds of Formulas (1), (2), and (3), conjugates thereof with a payload (P), pharmaceutical compositions thereof, methods of delivering the conjugates to subjects or cells, and methods of treating a disease or condition by administering such conjugates.

Abstract: A flow rate distribution method and apparatus and a work machine. The flow rate distribution method includes: acquiring a current actual displacement of each working element on a work machine; performing time integration on a current speed of each working element to obtain a current target displacement of each working element; determining a current displacement deviation of each working element based on the current actual displacement of each working element and the current target displacement of each working element; and distributing a current pump control flow rate of the work machine based on the current displacement deviation of each working element. According to the flow rate distribution method, when a plurality of working elements of a work machine operate, a current pump control flow rate can be accurately distributed.

Abstract: A multi-cluster system includes: a plurality of clusters in which an application is deployed, where a plurality of instances of the application are distributed in the plurality of clusters, each cluster includes a native scaling module, and the native scaling module is configured to increase or decrease a quantity of instances in the cluster to implement single-cluster instance autoscaling; and a management apparatus, configured to manage the plurality of clusters. According to this application, single-cluster autoscaling and cross-cluster autoscaling can be implemented, migration costs can be reduced, large-scale reconstruction of an existing system can be avoided, and compatibility can be implemented.

Abstract: The present disclosure relates to compositions, methods, processes, kits and devices for the selection, design, preparation, manufacture, formulation, and/or use of a polynucleotide having an Internal Ribosome Entry Site (IRES) sequence, an IRES-like sequence or a combination thereof. In particular, the present disclosure relates to compositions, methods, processes, kits and devices for the selection, design, preparation, manufacture, formulation, and/or use of a circular polynucleotide (e.g., a circular RNA). The present disclosure also relates to a method of improving expression, functional stability, immunogenicity, ease of manufacturing and/or half-life of a therapeutic product encoded by the circular RNA.

Abstract: A flow rate distribution method and apparatus and a work machine. The flow rate distribution method includes: acquiring a current actual displacement of each working element on a work machine; performing time integration on a current speed of each working element to obtain a current target displacement of each working element; determining a current displacement deviation of each working element based on the current actual displacement of each working element and the current target displacement of each working element; and distributing a current pump control flow rate of the work machine based on the current displacement deviation of each working element. According to the flow rate distribution method, when a plurality of working elements of a work machine operate, a current pump control flow rate can be accurately distributed.

Abstract: The present invention relates to a construct and method for preparing a circular RNA, and the use of the circular RNA. In particular, the present invention relates to a construct and method for preparing a circular RNA on the basis of a group II intron, and the use of the circular RNA.

Abstract: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.

Abstract: The present disclosure provides compositions comprising synthetic site-specific RNA editing entities engineered to target pathogenic RNA comprising a CAG repeat associated with a CAG repeat disorder. Also disclosed herein are methods of treating the CAG repeat disorders of the present disclosure, such as Huntington's disease with the compositions and pharmaceutical formulations comprising the compositions disclosed herein.

Abstract: Disclosed are RNA site-directed editing using artificially constructed RNA editing enzymes and related uses. Provided is the fusion of an RNA recognition domain for binding RNA and a functional effector domain to form a new functional protein. The new functional protein specifically targets target RNA by means of the recognition domain and performs RNA editing using the effector domain.

Abstract: Provided are a circular RNA construct and application thereof. The circular RNA construct has a structure represented by formula I in the 5?-3? direction: TI-Z1-Z2 (I), wherein TI is a translation initiation element, Z1 is an expression cassette for exogenous protein expression, and Z2 is nothing or another element.

Abstract: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.

Abstract: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.

Abstract: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.

Abstract: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.

Abstract: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.

Abstract: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.

Abstract: The present invention provides sequence specific restriction enzymes for site-specific cleavage of RNA, as well as methods of their use.